source
- Bayer's asundexian receives FDA approval for stroke preventionBayer announced that the U.S. Food and Drug Administration has approved its oral anticoagulant asundexian for stroke prevention. The drug is indicated to lower the risk of subsequent stroke in pati…
- Beam Therapeutics' base-edited sickle cell therapy shows success in Phase 1/2 trialBeam Therapeutics announced on Tuesday that its base-edited gene therapy for sickle cell disease met its primary endpoints in a Phase 1/2 study. The trial demonstrated that a single administration…